Non Small Cell Lung Cancer (NSCLC)

Stage III Met - IV 1st Line

Adenocarcinoma Neversmoking

EGFR Exon 20 Insertions

EGFR Mutant (Not Exon 20)

Without Actionable Genomic Alterations

LUN0112
Phase II Carboplatin + Pemetrexed + Bevacizumab +/- Atezolizumab in Stage IV Non-Squamous NSCLC
Pt: Wakelee
Sponsor: NCI-TH

LUN0113
Phase III TAK-788 First-Line Tx vs Platinum-Based Chemo in NSCLC w/ EGFR Exon 20 Insertion Mutations
Pt: Neal
Sponsor: Takeda

ECOG-ACRIN-EA5182
Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab versus Osimertinib (AZD9291) Alone as First-Line Treatment in Metastatic EGFR-Mutant NSCLC
Pt: Neal
Sponsor: ECOG-ACRIN

LUN0125
Phase II Sacituzumab Govitecan Combinations in First-Line Treatment of Advanced or Metastatic Non-Small-Cell Lung Cancer Without Actionable Genomic Alterations
Pt: Neal
Sponsor: Gilead Sciences, Inc.